Chair Professor School of Medicine
Mingzhao Xing, M.D., Ph.D., has been tenured Professor of Medicine since 2011 at the Johns Hopkins University School of Medicine. He is also Professor of Oncology, Pathology, and Cellular & Molecular Medicine, Director of the Johns Hopkins Thyroid Tumor Center, and Chief of the Laboratory for Cellular and Molecular Thyroid Research at the Johns Hopkins University School of Medicine. He graduated in 1984 from the Medicine Branch of the Second Military Medical University in Shanghai, China and received a Ph.D. in 1993 in Physiology and Biophysics from Case Western Reserve University in Cleveland, Ohio, USA. He completed a four-year Postdoctoral Research Fellowship in Molecular Pharmacology in 1997 at National Institutes of Health (NIH) and the University of California, San Diego, a three-year Residency in Internal Medicine in 2000 at Greater Baltimore Medical Center (honored with the Best Resident Award), and a three-year Clinical Fellowship in Endocrinology, Diabetes & Metabolism in 2003 at the Johns Hopkins Hospital in Baltimore, Maryland, USA. For his outstanding performance on the endocrine fellowship program of the Johns Hopkins Department of Medicine, upon graduation he was recruited to the Department’s faculty as an Assistant Professor of Medicine in 2003. He subsequently rose to Associate Professor in 2006 and tenured Full Professor in 2011 at the Johns Hopkins School of Medicine. American board-certified dually in Internal Medicine and Endocrinology & Metabolism, Dr. Xing has been working for the last nearly two decades at Johns Hopkins Hospital as an internist/endocrine subspecialty consultant and teaching attending while directing the Cellular and Molecular Thyroid Research Laboratory as a physician scientist at the Johns Hopkins School of Medicine.
Dr. Xing’s main clinical and research interests are in thyroid diseases, particularly thyroid dysfunctions and thyroid tumor. As a continuously well-funded Principal Investigator, his research has focused on studying molecular mechanisms and genetic basis of thyroid tumor and their clinical translation. He holds/co-holds ten USA patents on such seminal thyroid research contributions as initial discovery and clinical characterization of the BRAF V600E and TERT promoter mutations in thyroid cancer and initial demonstration of targeting BRAF/MEK to restore thyroid gene expression and radioiodine uptake for radioiodine treatment of thyroid cancer. His work has been heavily referenced in the clinical guidelines for the management of thyroid tumors of authoritative organizations, such as the American Thyroid Association, and has had a profound impact on today's molecular-based precision management of thyroid tumor.
Publications Read More
Lab members Read More
The positioning of the medical school of SUSTech is to build a research-oriented medical school rooted in shenzhen, facing China and the world as well as the cultural integration of science and technology and medicine, with first-class level and internationalization. Our mission is to cultivate leading medical talents with international vision, pioneering spirit and innovation ability, as well as moral integrity, explore medical unknowns, lead first-class scientific research, promote medical development, pursue exquisite medical technology and medical treatment, and provide high-quality clinical services.